Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
ANIKthis companyAnika Therapeutics, Inc.	$14.69	-12.64×	0.96×	1.22×	-29.78×	-96.2%	56.6%	-9.8%	-9.6%	-7.6%	-6.5%	3.2%	0.18×	8.73×	0×	4.72×	0.0%	5	3.79	2	C+
ANIXAnixa Biosciences, Inc.	$3.15	-12.15×	8.84×	0×	-12.1×	-99.1%	0.0%	0.0%	0.0%	-72.1%	-82.7%	-5.4%	0.01×	0.09×	0×	8.08×	0.0%	2	10.28	2	C
APYXApyx Medical Corporation	$2.94	-12.96×	10.15×	2.79×	-33.8×	-263.4%	36.0%	-12.2%	-21.2%	-77.1%	-11.6%	-6.2%	2.71×	-1.66×	-1.15×	5×	0.0%	3	0.94	1	D+
ARAYAccuray Incorporated	$3.95	-0.64×	0.76×	0.08×	-27.22×	-1195.4%	27.7%	-6.6%	-12.2%	-118.0%	-10.1%	-40.6%	4.41×	-22.28×	-0.75×	1.5×	0.0%	3	-0.49	2	C
AVRAnteris Technologies Global Corp.	$5.98	-1.96×	-1,980.52×	96.28×	-1.88×	-109.5%	-16.6%	-4908.2%	-4921.3%	101230.1%	-4256.3%	-43.3%	-24.54×	0.11×	-1,286.22×	0.73×	0.0%	3	13.63	2	C
LNSRLENSAR Inc	$5.51	-4.05×	-5.34×	2.38×	-4.33×	-955.2%	46.4%	-42.1%	-58.7%	131.7%	-77.8%	-10.7%	-0.11×	0.34×	0×	1.15×	0.0%	5	0.82	3	B+
Peer median	—	-4.05×	0.76×	2.38×	-12.1×	-263.4%	27.7%	-12.2%	-21.2%	-72.1%	-77.8%	-10.7%	0.01×	0.09×	-0.75×	1.5×	0.0%	3	0.94	2	—